Source: Annual Congress 2010 - Combination therapy in asthma and COPD
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
A. Bodzenta-Lukaszyk, G. Pulka, A. Dymek, H. Mansikka (Bialystok, Cracow, Strzelce Opolskie, Poland; Cambridge, United Kingdom). Fluticasone propionate/formoterol fumarate combination therapy has an efficacy and safety profile similar to that of its individual components administered concurrently in the treatment of asthma. Eur Respir J 2010; 36: Suppl. 54, 1207

Member's Comments

No comment yet.

Related content which might interest you: Fluticasone propionate/formoterol fumarate combination therapy has comparable efficacy to its individual components administered concurrently Source: Annual Congress 2011 - Airways disease comorbidities and general aspects Year: 2011 Long-term treatment with fluticasone propionate/formoterol fumarate (FLUT/FORM) combination therapy is well-tolerated and provides sustained effectiveness in paediatric patients with asthma Source: Annual Congress 2011 - Treating childhood asthma Year: 2011 Fluticasone propionate/formoterol fumarate combination therapy is equally effective and well-tolerated when administered with or without a spacer device to patients with asthma Source: Annual Congress 2011 - Drug delivery and pharmacokinetics II Year: 2011 Asthma exacerbation with fluticasone propionate/formoterol fumarate combination therapy versus its individual components Source: Annual Congress 2012 - Asthma treatment: efficacy and safety Year: 2012 Efficacy and safety of medium and high doses of mometasone furoate/formoterol combination treatment in subjects with severe asthma Source: Annual Congress 2010 - Aspects of severe asthma Year: 2010 Fluticasone propionate/formoterol fumarate combination therapy is more effective than fluticasone propionate alone in the treatment of asthma Source: Annual Congress 2010 - Combination therapy in asthma and COPD Year: 2010 Fluticasone propionate/formoterol fumarate combination therapy is as effective as fluticasone propionate/salmeterol xinafoate, but has a more rapid onset of action in the treatment of asthma Source: Annual Congress 2010 - Combination therapy in asthma and COPD Year: 2010 Effect of treatment with mometasone furoate/formoterol combination on rescue medication use Source: Annual Congress 2010 - Combination therapy in asthma and COPD Year: 2010 Efficacy and safety of combined mometasone furoate/formoterol 100/10μg twice daily in subjects with asthma inadequately controlled on low-dose inhaled corticosteroids Source: Annual Congress 2010 - Combination therapy in asthma and COPD Year: 2010 Effectiveness and safety of fluticasone propionate/salmeterol 250/50mcg administered once daily to patients with persistent asthma Source: Eur Respir J 2004; 24: Suppl. 48, 309s Year: 2004 Initial maintenance therapy with fluticasone propionate/ salmeterol combination product provides superior asthma control versus montelukast or fluticasone propionate alone Source: Eur Respir J 2002; 20: Suppl. 38, 386s Year: 2002 Fluticasone propionate/formoterol fumarate combination therapy has superior efficacy to both fluticasone and formoterol alone Source: Annual Congress 2011 - Drug delivery and pharmacokinetics II Year: 2011 Fluticasone propionate/formoterol fumarate (FLUT/FORM) combination therapy has comparable efficacy to fluticasone propionate/salmeterol xinafoate (FLUT/SAL) in paediatric patients with asthma Source: Annual Congress 2011 - Treating childhood asthma Year: 2011 The fluticasone/salmeterol combination product is superior to montelukast as first-line asthma control Source: Eur Respir J 2001; 18: Suppl. 33, 263s Year: 2001 Eight weeks of treatment with tiotropium plus fluticasone (t+f) produces an equally effective therapeutic response as salmeterol plus fluticasone (s+f) in subjects with moderate-to-severe asthma Source: Annual Congress 2009 - Towards improving asthma control Year: 2009 Clinical efficacy of once-daily mometasone furoate in children with persistent asthma switched from treatment with fluticasone propionate Source: Annual Congress 2011 - Airways disease comorbidities and general aspects Year: 2011 Fluticasone furoate (FF), a once-daily inhaled corticosteroid (ICS), demonstrates dose-response efficacy in patients symptomatic on non-steroidal asthma therapy Source: Annual Congress 2010 - New treatments for asthma and COPD Year: 2010 Efficacy and safety of fluticasone/formoterol compared to fluticasone alone in patients with asthma Source: Annual Congress 2012 - Translational respiratory medicine in asthma and COPD Year: 2012 Twice-daily fluticasone propionate (fp)/formoterol fumarate (fm) HFA PMDI combination therapy is safe, efficacious and reduces asthma exacerbations in patients with moderate to severe asthma Source: Annual Congress 2009 - Towards improving asthma control Year: 2009 Twice-daily fluticasone propionate (fp)/formoterol fumarate (fm) HFA PMDI combination therapy is safe, efficacious and reduces asthma exacerbations in patients with mild to moderate asthma Source: Annual Congress 2009 - Aspects of uncontrolled asthma Year: 2009